Vantage logo

Covid-19 divides the biggest medtechs

Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.

Vantage logo

Covid-19 hits Europe drug stocks hardest

US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.

Vantage logo

Covid-19 infects global drug stocks

The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.

Vantage logo

The big cap empire strikes back

If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.